AI brief of an SEC Form 8-K · Healthcare Services Group (HCSG)

HCSG Q2 net loss of $32.4 million on 7.6% revenue growth; Genesis charge weighs

Mixed Impact 4 of 5 earnings Written later

Healthcare Services Group reported second-quarter revenue of $458.5 million, up 7.6% from a year earlier, but posted a net loss of $32.4 million, or $0.44 per diluted share, compared with a net loss of $1.8 million a year earlier. The loss includes a $0.65 per share non-cash charge tied to the previously announced Genesis HealthCare restructuring. The company raised its 2025 cash flow from operations forecast, excluding the change in payroll accrual, and announced a $50.0 million share repurchase plan over the next 12 months.

Key points

  • Revenue of $458.5 million for the three months ended June 30, 2025, up 7.6% over the prior year
  • Net loss of $32.4 million, or $0.44 per diluted share, including a $0.65 per share non-cash Genesis restructuring charge ($61.2 million pretax)
  • 2025 cash flow from operations forecast, excluding payroll accrual changes, raised to $70.0 to $85.0 million from $60.0 to $75.0 million
  • Board-authorized plan to repurchase $50.0 million of common stock over 12 months; $7.6 million repurchased in the second quarter

The filing

CompanyHealthcare Services Group (HCSG)
Form8-K, current report
Filed with the SECJul 23, 2025, 7:10 AM ET
Accession number0000731012-25-000097

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:58 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 23, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.